← Leaderboards
Thomas N Wight
University Of Washington
$8,337,304
Attributed
$9,463,186
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–14$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$9,463,186 · 8
By mechanism
P01$5,019,005 · 3
R01$2,941,419 · 2
R21$810,750 · 1
R41$677,012 · 1
R13$15,000 · 1
Top collaborators
- Robert B Vernon4 shared
Most similar at University Of Washington
Same institution · by research overlap
- Michael Ailion$4,506,906
- Kanchan A Chitaley$2,668,818
- Joseph David Mougous$10,581,472
- May J Reed$5,889,471
- Alexander Richard Paredez$5,038,624
Others in their field
Top investigators on “Proteoglycan”
- Pyong Woo Park · Baylor College Of Medicine$19,694,248
- Jeffrey D Esko · University Of California San Diego$19,208,444
- Ravinder R Regatte · New York University School Of Medicine$17,649,381
- Renato V. Iozzo · Thomas Jefferson University$15,775,453
- Yu Yamaguchi · Sanford Burnham Prebys Medical Discovery Institute$12,492,066
- David E Birk · Thomas Jefferson University$11,986,022
Research focus
ProteoglycanExtracellular MatrixProductionVersicanStructureCollagenFibroblastsMacrophageResponseBlood VesselsCellsPublic Health Medicine (Field)BaseAdhesionsResearch StudyLaboratory RatElastic TissueMalignant NeoplasmsImmune ResponseInflammatoryProteinsIn VitroHuman TissuePhenotype
Grant awards (25)
Engineering vascular replacements for strength and elasticity$564,034
R01 · FY2014 · EB · contact PI
Extracellular Matrix in the Innate Immune Response in Lung Inflammation$411,439
P01 · FY2014 · HL · contact PI
Engineering vascular replacements for strength and elasticity$548,333
R01 · FY2013 · EB · contact PI
Extracellular Matrix in the Innate Response in Lung Inflammation$404,335
P01 · FY2013 · HL · contact PI
Engineering vascular replacements for strength and elasticity$581,472
R01 · FY2012 · EB · contact PI
Extracellular Matrix in the Innate Response in Lung Inflammation$552,321
P01 · FY2012 · HL · contact PI
Targeting the Extracellular Matrix to Inhibit Saphenous Vein Graft (SVG) Failure$334,031
R41 · FY2012 · HL · contact PI
Engineering vascular replacements for strength and elasticity$557,926
R01 · FY2011 · EB · contact PI
Extracellular Matrix in the Innate Response in Lung Inflammation$496,492
P01 · FY2011 · HL · contact PI
Targeting the Extracellular Matrix to Inhibit Saphenous Vein Graft (SVG) Failure$342,981
R41 · FY2011 · HL · contact PI
Pro-Inflammatory ECM: Key Roles for Hyaluronan and Versican$526,297
P01 · FY2010 · HL · contact PI
Extracellular Matrix in the Innate Response in Lung Inflammation$514,947
P01 · FY2010 · HL · contact PI
Pro-Inflammatory ECM: Key Roles for Hyaluronan and Versican$440,000
P01 · FY2009 · HL · contact PI
Pro-Inflammatory ECM: Key Roles for Hyaluronan and Versican$435,000
P01 · FY2008 · HL · contact PI
Regulation of Cell Function by Matricellular Hevin$344,827
R01 · FY2008 · CA · contact PI
2008 Proteoglycans Gordon Research Conference$15,000
R13 · FY2008 · AR · contact PI
Regulation of Cell Function by Matricellular Hevin$344,827
R01 · FY2007 · CA · contact PI
Pro-Inflammatory ECM: Key Roles for Hyaluronan and Versican$438,875
P01 · FY2006 · HL · contact PI
Use of Proteoglycan-Genes to Engineer Vascular Tissue$263,250
R21 · FY2004 · HL
Use of Proteoglycan-Genes to Engineer Vascular Tissue$210,092
R21 · FY2003 · HL
Use of Proteoglycan-Genes to Engineer Vascular Tissue$63,658
R21 · FY2003 · HL
Use of Proteoglycan-Genes to Engineer Vascular Tissue$273,750
R21 · FY2002 · HL
PROTEOGLYCANS, GLYCOSAMINOGLYCANS AND ATHEROSCLEROSIS$266,433
P01 · FY2002 · HL
PROTEOGLYCANS, GLYCOSAMINOGLYCANS AND ATHEROSCLEROSIS$266,433
P01 · FY2001 · HL
PROTEOGLYCANS, GLYCOSAMINOGLYCANS AND ATHEROSCLEROSIS$266,433
P01 · FY2000 · HL